Month: January 2024

Sagard Healthcare purchased a 1% royalty in Tyvaso DPI® net sales Purchase price of $150 million; additional potential milestone payment of up to $50 millionWESTLAKE VILLAGE, Calif., Jan. 02, 2024 (GLOBE NEWSWIRE) — MannKind Corporation (Nasdaq: MNKD) announced that on December 27, 2023 it sold a 1% royalty in net sales of Tyvaso DPI® (treprostinil) inhalation powder in exchange for up to $200 million, including the purchase price of $150 million and an additional potential milestone payment of up to $50 million. United Therapeutics Corporation licensed Tyvaso DPI from MannKind in 2018 and began marketing it in June 2022 for the treatment of pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease following U.S. FDA approval. Pursuant to a license agreement with United Therapeutics,...

Company Announcement No. 1080 On 24 October 2023, we initiated a share buyback programme, as described in Company Announcement No. 1066. According to the programme, the company will in the period from 24 October 2023 until 31 January 2024 purchase own shares up to a maximum value of DKK 2,500 million, and no more than 4,000,000 shares, corresponding to 1.83% of the share capital at commencement of the programme. The programme has been implemented in accordance with Regulation No. 596/2014 of the European Parliament and Council of 16 April 2014 (“MAR”) (save for the rules on share buyback programmes set out in MAR article 5) and the Commission Delegated Regulation (EU) 2016/1052, also referred to as the Safe Harbour rules. The following transactions have been recorded under the programme:Trading day Trading platform   Number of shares...

In week 52 2023, SKEL fjárfestingafélag hf. purchased in total 1,098,601 own shares for total amount of 16,258,595 ISK as follows:Date Time Purchased shares Proce Purchase price Total own shares27.12.2023 10:43:00 400,000    14.75    5,900,000    56,856,141   28.12.2023 10:10:00 660,000    14.80    9,768,000    57,516,141   29.12.2023 10:28:00 38,601    15.30    590,595    57,554,742       1,098,601   16,258,595 57,554,742The execution of the buy-back programme is in accordance with Chapter VIII of the Company Act No 2/1995, Article 5 of the Regulation of the European parliament and of the Council (EU) on Market Fraud No. 60/2021, the Commissions Delegated Regulation No. 2016/1052 and the Act on Actions against Market Fraud No. 60/2021. Before the purchase SKEL held 18,518,518 own shares. SKEL fjárfestingafélag...

PRESS RELEASE, January 2, 2024 Rapala VMC Corporation has sold group’s entire injection molding business to a Finnish mold and injection molded parts manufacturer Muottituote Group Oy with an agreement signed on the December 22, 2023. With the transaction, Muottituote Group Oy acquires Rapala VMC Corporation’s subsidiary KL-Teho Oy’s real estate located in Korpilahti, Finland, along with the injection molding operations, equipment, and personnel. “The completed transaction is part of Rapala’s strategy to focus on core business and release capital. Rapala has been collaborating with Muottituote Group for decades, and with this deal, the collaboration is further intensified. We have entered into a multi-year procurement agreement with Muottituote Group, ensuring timely deliveries of components to the Rapala VMC Group. This...

Company announcement no. 01 In company announcement no. 8 2023, Spar Nord announced a share buyback programme of up to DKK 300 million. The share buyback was initiated on 13 February 2023. The purpose of the share buyback is to reduce the bank’s share capital by the shares acquired under the programme, and the programme is executed pursuant to Regulation (EU) No 596/2014 of 16 April 2014 (“Market Abuse Regulation”). In week 52 the following transactions were made under the share buyback programme.  Number of shares Average purchase price Transaction value (DKK)Accumulated from last announcement 2,669,100   289,385,84625 December 2023 – – –26 December 2023 – – –27 December 2023 9,000 107.07 963,63028 December 2023 7,000 107.07 749,49029 December 2023 4,000 106.91 427,640Total...

SHENZHEN, CHINA, Jan. 02, 2024 (GLOBE NEWSWIRE) — On 29 December, 2023, PharmaGend Global Medical Services Pte. Ltd. (“PharmaGend”), jointly invested by China Medical System Holdings Limited (“CMS”), through its wholly-owned subsidiary CMS MEDICAL VENTURE PTE. LTD., and its non-wholly owned subsidiary Rxilient Health Pte. Ltd., with Pharmaron (Hong Kong) International Limited (“Pharmaron”) * and Healthy Goal Limited (“Legend Fund”), has entered into a lease agreement for the building and property located in Tuas, Singapore and completed the purchase of certain production machines and equipment from Strides Pharma Global Pte. Ltd. ( defined as “Singapore manufacturing plant ”). Based on over 30 years of global investment and acquisition experience and proven commercialization capabilities, CMS actively implements an internationalization...